Systemic Scleroderma Treatment Market Size, Share & Trends Analysis Report By Drug Class (Immunosuppressors, PDE-5 Inhibitors, Endothelin Receptor Antagonist, Prostacyclin Analogues), By Region, And Segment Forecasts, 2020 - 2027
This report can be delivered to the clients within 72 Business Hours
Systemic Scleroderma Treatment Market Growth & Trends
The global systemic scleroderma treatment market size is expected to reach USD 1.9 billion by 2027, according to a new study by Grand View Research Inc. The market is expected to expand at a CAGR of 4.0% from 2020 to 2027. The market is largely attributable to the strong presence of therapies used off-label that include small molecule therapies including branded, generics, and OTC drugs.
The mix of several indications and drug classes engenders a fragmented space with multiple players. Johnson and Johnson Services, Inc. dominated the market with a share of 23.7% in the year 2019. United Therapeutics Corporation is the second biggest service provider in the space with a significant share in 2019. The other players such as F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline plc, Novartis AG, and Pfizer Inc. also have a significant share of the global market.
The on-label treatment is in the development phase. Major players with therapies undergoing clinical development are divided into two sorts. There are some developing new compounds, whereas certain other established players are seen repurposing their drugs (currently approved for other indications) for scleroderma use. In September 2019, Boehringer Ingelheim GmbH announced the U.S. FDA approval of Ofev for the treatment of interstitial lung disease in patients with systemic sclerosis.
Supplemental indication approval is one of the most common strategies adopted by pharmaceutical players thriving in the space. There are several pharmaceutical companies adopting strategies that favor the pharmaceutical industry in offsetting high development costs.
For instance, companies are developing promising product candidates such as Ziritaxestat, an autotaxin inhibitor from Galapagos NV in collaboration with Gilead Sciences, Inc. Furthermore, Horizon Therapeutics plc entered the space with the acquisition of Curzion Pharmaceuticals, Inc. in April 2020 that is developing HZN-825 and Tepezza.
Systemic Scleroderma Treatment Market Report Highlights
Systemic Scleroderma Treatment Market Growth & Trends
The global systemic scleroderma treatment market size is expected to reach USD 1.9 billion by 2027, according to a new study by Grand View Research Inc. The market is expected to expand at a CAGR of 4.0% from 2020 to 2027. The market is largely attributable to the strong presence of therapies used off-label that include small molecule therapies including branded, generics, and OTC drugs.
The mix of several indications and drug classes engenders a fragmented space with multiple players. Johnson and Johnson Services, Inc. dominated the market with a share of 23.7% in the year 2019. United Therapeutics Corporation is the second biggest service provider in the space with a significant share in 2019. The other players such as F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline plc, Novartis AG, and Pfizer Inc. also have a significant share of the global market.
The on-label treatment is in the development phase. Major players with therapies undergoing clinical development are divided into two sorts. There are some developing new compounds, whereas certain other established players are seen repurposing their drugs (currently approved for other indications) for scleroderma use. In September 2019, Boehringer Ingelheim GmbH announced the U.S. FDA approval of Ofev for the treatment of interstitial lung disease in patients with systemic sclerosis.
Supplemental indication approval is one of the most common strategies adopted by pharmaceutical players thriving in the space. There are several pharmaceutical companies adopting strategies that favor the pharmaceutical industry in offsetting high development costs.
For instance, companies are developing promising product candidates such as Ziritaxestat, an autotaxin inhibitor from Galapagos NV in collaboration with Gilead Sciences, Inc. Furthermore, Horizon Therapeutics plc entered the space with the acquisition of Curzion Pharmaceuticals, Inc. in April 2020 that is developing HZN-825 and Tepezza.
Systemic Scleroderma Treatment Market Report Highlights
- The immunosuppressors segment held the largest revenue share in 2019, followed by prostacyclin analogues
- The high preference for immunosuppressants owing to the favorable reimbursement scenario associated with this drug class will support its dominant share in this space
- The U.S. held the majority of the revenue share in 2019. Expected label expansions and the expected launch of first-in-class therapies coupled with an evolving reimbursement landscape for orphan drugs are expected to support market growth
- Europe trails with a lower share as compared to the U.S. majorly due to higher use of generics and biosimilars for off-label treatment of scleroderma
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market segmentation & scope
1.2. Market definition
1.3. Information procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources & third party perspectives
1.3.4. Primary research
1.4. Information analysis
1.4.1. Data analysis models
1.5. Market formulation & data visualization
1.6. Model Details
1.7. Global Market: CAGR Calculation
1.8. Research assumptions
1.9. List of primary and secondary sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
2.4. Market Summary
CHAPTER 3. SYSTEMIC SCLERODERMA TREATMENT MARKET VARIABLES, TRENDS & SCOPE
3.1. Systemic Scleroderma Treatment Market Lineage outlook
3.1.1. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.1.1. Lack of curative therapies attract new players
3.3.1.2. Growing prevalence of Systemic Scleroderma Treatment
3.3.1.3. Developed regions present major opportunity markets
3.3.1.4. Expanding pharmaceutical pipeline
3.3.2. Market Restraint Analysis
3.3.2.1. Failure of late-stage clinical trial candidates
3.3.2.2. Lack of well-defined regulatory and reimbursement framework impedes growth in developing regions
3.3.2.3. Reimbursement uncertainties in developed regions pose obstacles
3.4. Systemic Scleroderma Treatment Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier Power: Moderate due to the presence of many suppliers
3.4.1.2. Buyer Power: Moderate owing to the presence of providers
3.4.1.3. Substitution Threat: Low owing to no substitutes
3.4.1.4. Threat from new entrant: Moderate due to high buyer switching cost
3.4.1.5. Competitive rivalry: High due to the presence of a large number of generic manufacturers
3.4.2. PESTEL Analysis
3.4.2.1. Political Landscape
3.4.2.2. Environmental Landscape
3.4.2.3. Social Landscape
3.4.2.4. Technology Landscape
3.4.2.5. Legal Landscape
CHAPTER 4. SYSTEMIC SCLERODERMA TREATMENT MARKET: DRUG CLASS ESTIMATES & TREND ANALYSIS
4.1. Definitions & Scope
4.2. Drug Class market share analysis, 2019 & 2027
4.3. Drug Class Dashboard
4.4. Global Systemic Scleroderma Treatment Market, by Drug Class, 2016 to 2027
4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following:
4.5.1. Immunosuppressors
4.5.1.1. Immunosuppressors Market, 2016 - 2027 (USD Million)
4.5.2. Phosphodiesterase 5 inhibitors - PHA
4.5.2.1. Phosphodiesterase 5 inhibitors - PHA Market, 2016 - 2027 (USD Million)
4.5.3. Endothelin Receptor Antagonists
4.5.3.1. Endothelin Receptor Antagonists Market, 2016 - 2027 (USD Million)
4.5.4. Prostacyclin Analogues
4.5.4.1. Prostacyclin Analogues Market, 2016 - 2027 (USD Million)
4.5.5. Calcium Channel Blockers
4.5.5.1. Calcium Channel Blockers Market, 2016 - 2027 (USD Million)
4.5.6. Others
4.5.6.1. Others Market, 2016 - 2027 (USD Million)
CHAPTER 5. SYSTEMIC SCLERODERMA TREATMENT MARKET: REGIONAL ESTIMATES & TREND ANALYSIS, BY DRUG CLASS, AND INDICATION
5.1. Regional Market Snapshot
5.2. Regional Market Share and Leading Players, 2019
5.2.1. North America
5.2.2. Europe
5.2.3. Asia Pacific
5.2.4. Latin America
5.2.5. Middle East & Africa
5.3. SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
5.3.1. North America
5.3.2. Europe
5.3.3. Asia Pacific
5.3.4. Latin America
5.3.5. Middle East & Africa
5.4. Market Size & Forecasts and Trend Analysis, 2019 to 2027:
5.4.1. North America
5.4.1.1. North America Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.1.2. U.S.
5.4.1.2.1. U.S. Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.1.3. Canada
5.4.1.3.1. Canada Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.2. Europe
5.4.2.1. Europe Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.2.2. U.K.
5.4.2.2.1. U.K. Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.2.3. Germany
5.4.2.3.1. Germany Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.2.4. Spain
5.4.2.4.1. Spain Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.2.5. France
5.4.2.5.1. France Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.2.6. Italy
5.4.2.6.1. Italy Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.3. Asia Pacific
5.4.3.1. Asia Pacific Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.3.2. China
5.4.3.2.1. China Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.3.3. Japan
5.4.3.3.1. Japan Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.3.4. India
5.4.3.4.1. India Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.3.5. Australia
5.4.3.5.1. Australia Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.4. Latin America
5.4.4.1. Latin America Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.4.2. Brazil
5.4.4.2.1. Brazil Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.4.3. Mexico
5.4.4.3.1. Mexico Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.4.4. Argentina
5.4.4.4.1. Argentina Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.5. Middle East Africa
5.4.5.1. MEA Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.5.2. South Africa
5.4.5.2.1. South Africa Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.5.3. Saudi Arabia
5.4.5.3.1. Saudi Arabia Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.5.4. UAE
5.4.5.4.1. UAE Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
CHAPTER 6. COMPANY PROFILES
6.1. Recent developments & impact analysis, by key market participants
6.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
6.3. Public Companies
6.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
6.3.2. Competitive Dashboard Analysis
6.3.3. Market Differentiators
6.4. Private Companies
6.4.1. Regional network map
6.5. Company Profiles
6.5.1. Johnson & Johnson Services, Inc.
6.5.1.1. Company Overview
6.5.1.2. Financial Performance
6.5.1.3. Product Benchmarking
6.5.1.4. Strategic Initiatives
6.5.2. Boehringer Ingelheim International GmbH
6.5.2.1. Company Overview
6.5.2.2. Financial Performance
6.5.2.3. Product Benchmarking
6.5.2.4. Strategic Initiatives
6.5.3. F. Hoffman La Roche Ltd.
6.5.3.1. Company Overview
6.5.3.2. Financial Performance
6.5.3.3. Product Benchmarking
6.5.3.4. Strategic Initiatives
6.5.4. United Therapeutics Corporation
6.5.4.1. Company Overview
6.5.4.2. Financial Performance
6.5.4.3. Product Benchmarking
6.5.4.4. Strategic Initiatives
6.5.5. Novartis AG
6.5.5.1. Company Overview
6.5.5.2. Financial Performance
6.5.5.3. Product Benchmarking
6.5.5.4. Strategic Initiatives
6.5.6. GlaxoSmithKline plc. (GSK)
6.5.6.1. Company Overview
6.5.6.2. Financial Performance
6.5.6.3. Product Benchmarking
6.5.6.4. Strategic Initiatives
6.5.7. Teva Pharmaceutical Industries Ltd.
6.5.7.1. Company Overview
6.5.7.2. Financial Performance
6.5.7.3. Product Benchmarking
6.5.7.4. Strategic Initiatives
6.5.8. Gilead Sciences Inc.
6.5.8.1. Company Overview
6.5.8.2. Financial Performance
6.5.8.3. Product Benchmarking
6.5.8.4. Strategic Initiatives
6.5.9. Pfizer Inc.
6.5.9.1. Company Overview
6.5.9.2. Financial Performance
6.5.9.3. Product Benchmarking
6.5.9.4. Strategic Initiatives
6.5.10. Mylan N.V.
6.5.10.1. Company Overview
6.5.10.2. Financial Performance
6.5.10.3. Product Benchmarking
6.5.10.4. Strategic Initiatives
1.1. Market segmentation & scope
1.2. Market definition
1.3. Information procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources & third party perspectives
1.3.4. Primary research
1.4. Information analysis
1.4.1. Data analysis models
1.5. Market formulation & data visualization
1.6. Model Details
1.7. Global Market: CAGR Calculation
1.8. Research assumptions
1.9. List of primary and secondary sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
2.4. Market Summary
CHAPTER 3. SYSTEMIC SCLERODERMA TREATMENT MARKET VARIABLES, TRENDS & SCOPE
3.1. Systemic Scleroderma Treatment Market Lineage outlook
3.1.1. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.1.1. Lack of curative therapies attract new players
3.3.1.2. Growing prevalence of Systemic Scleroderma Treatment
3.3.1.3. Developed regions present major opportunity markets
3.3.1.4. Expanding pharmaceutical pipeline
3.3.2. Market Restraint Analysis
3.3.2.1. Failure of late-stage clinical trial candidates
3.3.2.2. Lack of well-defined regulatory and reimbursement framework impedes growth in developing regions
3.3.2.3. Reimbursement uncertainties in developed regions pose obstacles
3.4. Systemic Scleroderma Treatment Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier Power: Moderate due to the presence of many suppliers
3.4.1.2. Buyer Power: Moderate owing to the presence of providers
3.4.1.3. Substitution Threat: Low owing to no substitutes
3.4.1.4. Threat from new entrant: Moderate due to high buyer switching cost
3.4.1.5. Competitive rivalry: High due to the presence of a large number of generic manufacturers
3.4.2. PESTEL Analysis
3.4.2.1. Political Landscape
3.4.2.2. Environmental Landscape
3.4.2.3. Social Landscape
3.4.2.4. Technology Landscape
3.4.2.5. Legal Landscape
CHAPTER 4. SYSTEMIC SCLERODERMA TREATMENT MARKET: DRUG CLASS ESTIMATES & TREND ANALYSIS
4.1. Definitions & Scope
4.2. Drug Class market share analysis, 2019 & 2027
4.3. Drug Class Dashboard
4.4. Global Systemic Scleroderma Treatment Market, by Drug Class, 2016 to 2027
4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following:
4.5.1. Immunosuppressors
4.5.1.1. Immunosuppressors Market, 2016 - 2027 (USD Million)
4.5.2. Phosphodiesterase 5 inhibitors - PHA
4.5.2.1. Phosphodiesterase 5 inhibitors - PHA Market, 2016 - 2027 (USD Million)
4.5.3. Endothelin Receptor Antagonists
4.5.3.1. Endothelin Receptor Antagonists Market, 2016 - 2027 (USD Million)
4.5.4. Prostacyclin Analogues
4.5.4.1. Prostacyclin Analogues Market, 2016 - 2027 (USD Million)
4.5.5. Calcium Channel Blockers
4.5.5.1. Calcium Channel Blockers Market, 2016 - 2027 (USD Million)
4.5.6. Others
4.5.6.1. Others Market, 2016 - 2027 (USD Million)
CHAPTER 5. SYSTEMIC SCLERODERMA TREATMENT MARKET: REGIONAL ESTIMATES & TREND ANALYSIS, BY DRUG CLASS, AND INDICATION
5.1. Regional Market Snapshot
5.2. Regional Market Share and Leading Players, 2019
5.2.1. North America
5.2.2. Europe
5.2.3. Asia Pacific
5.2.4. Latin America
5.2.5. Middle East & Africa
5.3. SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
5.3.1. North America
5.3.2. Europe
5.3.3. Asia Pacific
5.3.4. Latin America
5.3.5. Middle East & Africa
5.4. Market Size & Forecasts and Trend Analysis, 2019 to 2027:
5.4.1. North America
5.4.1.1. North America Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.1.2. U.S.
5.4.1.2.1. U.S. Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.1.3. Canada
5.4.1.3.1. Canada Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.2. Europe
5.4.2.1. Europe Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.2.2. U.K.
5.4.2.2.1. U.K. Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.2.3. Germany
5.4.2.3.1. Germany Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.2.4. Spain
5.4.2.4.1. Spain Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.2.5. France
5.4.2.5.1. France Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.2.6. Italy
5.4.2.6.1. Italy Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.3. Asia Pacific
5.4.3.1. Asia Pacific Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.3.2. China
5.4.3.2.1. China Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.3.3. Japan
5.4.3.3.1. Japan Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.3.4. India
5.4.3.4.1. India Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.3.5. Australia
5.4.3.5.1. Australia Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.4. Latin America
5.4.4.1. Latin America Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.4.2. Brazil
5.4.4.2.1. Brazil Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.4.3. Mexico
5.4.4.3.1. Mexico Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.4.4. Argentina
5.4.4.4.1. Argentina Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.5. Middle East Africa
5.4.5.1. MEA Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.5.2. South Africa
5.4.5.2.1. South Africa Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.5.3. Saudi Arabia
5.4.5.3.1. Saudi Arabia Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.5.4. UAE
5.4.5.4.1. UAE Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
CHAPTER 6. COMPANY PROFILES
6.1. Recent developments & impact analysis, by key market participants
6.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
6.3. Public Companies
6.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
6.3.2. Competitive Dashboard Analysis
6.3.3. Market Differentiators
6.4. Private Companies
6.4.1. Regional network map
6.5. Company Profiles
6.5.1. Johnson & Johnson Services, Inc.
6.5.1.1. Company Overview
6.5.1.2. Financial Performance
6.5.1.3. Product Benchmarking
6.5.1.4. Strategic Initiatives
6.5.2. Boehringer Ingelheim International GmbH
6.5.2.1. Company Overview
6.5.2.2. Financial Performance
6.5.2.3. Product Benchmarking
6.5.2.4. Strategic Initiatives
6.5.3. F. Hoffman La Roche Ltd.
6.5.3.1. Company Overview
6.5.3.2. Financial Performance
6.5.3.3. Product Benchmarking
6.5.3.4. Strategic Initiatives
6.5.4. United Therapeutics Corporation
6.5.4.1. Company Overview
6.5.4.2. Financial Performance
6.5.4.3. Product Benchmarking
6.5.4.4. Strategic Initiatives
6.5.5. Novartis AG
6.5.5.1. Company Overview
6.5.5.2. Financial Performance
6.5.5.3. Product Benchmarking
6.5.5.4. Strategic Initiatives
6.5.6. GlaxoSmithKline plc. (GSK)
6.5.6.1. Company Overview
6.5.6.2. Financial Performance
6.5.6.3. Product Benchmarking
6.5.6.4. Strategic Initiatives
6.5.7. Teva Pharmaceutical Industries Ltd.
6.5.7.1. Company Overview
6.5.7.2. Financial Performance
6.5.7.3. Product Benchmarking
6.5.7.4. Strategic Initiatives
6.5.8. Gilead Sciences Inc.
6.5.8.1. Company Overview
6.5.8.2. Financial Performance
6.5.8.3. Product Benchmarking
6.5.8.4. Strategic Initiatives
6.5.9. Pfizer Inc.
6.5.9.1. Company Overview
6.5.9.2. Financial Performance
6.5.9.3. Product Benchmarking
6.5.9.4. Strategic Initiatives
6.5.10. Mylan N.V.
6.5.10.1. Company Overview
6.5.10.2. Financial Performance
6.5.10.3. Product Benchmarking
6.5.10.4. Strategic Initiatives
LIST OF TABLES
TABLE 1 List Of Abbreviation
TABLE 2 North America Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 3 U.S. Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 4 Canada Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 5 Europe Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 6 U.K. Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 7 Germany Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 8 Italy Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 9 France Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 10 Spain Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 11 Asia Pacific Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 12 Japan Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 13 China Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 14 India Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 15 Australia Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 16 Latin America Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 17 Brazil Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 18 Mexico Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 19 Argentina Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 20 MEA Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 21 South Africa Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 22 Saudi Arabia Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 23 UAE Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 1 List Of Abbreviation
TABLE 2 North America Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 3 U.S. Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 4 Canada Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 5 Europe Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 6 U.K. Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 7 Germany Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 8 Italy Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 9 France Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 10 Spain Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 11 Asia Pacific Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 12 Japan Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 13 China Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 14 India Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 15 Australia Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 16 Latin America Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 17 Brazil Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 18 Mexico Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 19 Argentina Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 20 MEA Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 21 South Africa Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 22 Saudi Arabia Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 23 UAE Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
LIST OF FIGURES
FIG. 1 Systemic scleroderma treatment: Market snapshot
FIG. 2 Systemic scleroderma treatment: Market segmentation
FIG. 3 Systemic scleroderma treatment: Market driver impact
FIG. 4 Systemic scleroderma treatment: Market restraint impact
FIG. 5 Penetration & growth prospect mapping
FIG. 6 SWOT analysis, by factor (Political & Legal Economic and Technological)
FIG. 7 Systemic scleroderma treatment market: Company market share (%), 2019 & 2027
FIG. 8 Systemic scleroderma treatment market: Drug classes outlook and key takeaways
FIG. 9 Systemic scleroderma treatment market: Drug class movement analysis
FIG. 10 Immunosuppressants market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 11 Endothelin receptor antagonists market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 12 Prostacyclin analogues market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 13 Calcium channel blockers market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 14 PDE - 5 inhibitors market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 15 Others market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 16 Systemic scleroderma treatment market: Regional outlook and key takeaways
FIG. 17 Systemic scleroderma treatment market: Regional movement analysis
FIG. 18 North America systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 19 U.S. systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 20 Canada systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 21 Europe systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 22 Germany systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 23 U.K. systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 24 France systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 25 Italy systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 26 Spain systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 27 Asia Pacific systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 28 Japan systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 29 China systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 30 India systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 31 Australia systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 32 Latin America systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 33 Brazil systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 34 Mexico systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 35 Argentina systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 36 Middle East systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 37 Saudi Arabia systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 38 South Africa systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 39 UAE systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 40 Strategic Framework
FIG. 1 Systemic scleroderma treatment: Market snapshot
FIG. 2 Systemic scleroderma treatment: Market segmentation
FIG. 3 Systemic scleroderma treatment: Market driver impact
FIG. 4 Systemic scleroderma treatment: Market restraint impact
FIG. 5 Penetration & growth prospect mapping
FIG. 6 SWOT analysis, by factor (Political & Legal Economic and Technological)
FIG. 7 Systemic scleroderma treatment market: Company market share (%), 2019 & 2027
FIG. 8 Systemic scleroderma treatment market: Drug classes outlook and key takeaways
FIG. 9 Systemic scleroderma treatment market: Drug class movement analysis
FIG. 10 Immunosuppressants market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 11 Endothelin receptor antagonists market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 12 Prostacyclin analogues market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 13 Calcium channel blockers market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 14 PDE - 5 inhibitors market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 15 Others market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 16 Systemic scleroderma treatment market: Regional outlook and key takeaways
FIG. 17 Systemic scleroderma treatment market: Regional movement analysis
FIG. 18 North America systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 19 U.S. systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 20 Canada systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 21 Europe systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 22 Germany systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 23 U.K. systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 24 France systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 25 Italy systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 26 Spain systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 27 Asia Pacific systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 28 Japan systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 29 China systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 30 India systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 31 Australia systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 32 Latin America systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 33 Brazil systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 34 Mexico systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 35 Argentina systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 36 Middle East systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 37 Saudi Arabia systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 38 South Africa systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 39 UAE systemic scleroderma treatment market estimates and forecast, 2016 - 2027 (USD Million)
FIG. 40 Strategic Framework
